1100 Corporate Square Drive
Helix Center, Suite 175
MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property (IP) portfolio.
Founder and CEO: Steven J. Hanley
Founder and CSO: Richard B. Dorshow
Please click here for clinical trial information.